Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III
Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III
复制标题
DOI：
10.1176/appi.ajp.2015.15070907
复制
发表时间：
2016-06-01
影响因子：
17.7
通讯作者：
Grant, Bridget F.
中科院分区：
文献类型：
--
作者：
Hasin, Deborah S.;Kerridge, Bradley T.;Grant, Bridget F.
目的：对大麻的态度正在发生变化，DSM-IV大麻使用障碍的患病率有所增加，DSM-5修改了大麻使用障碍标准。因此，需要更新有关DSM-5大麻使用disorder.Method的患病率，人口统计学特征，精神病合并症，残疾和治疗的信息：在2012-2013年，36，309名参与者>= 18岁接受了采访，在全国流行病学调查酒精和相关条件-III。精神和物质使用障碍采用酒精使用障碍和相关残疾访谈量表-5进行评估。结果：12个月和终生大麻使用障碍的患病率分别为2.5%和6.3%。在12个月和终身诊断的人中，每年使用大麻的平均天数分别为225.3（SE=5.7）和274.2（SE=3.8）。男性、美洲原住民、未婚者、低收入者和年轻人（例如，年龄在18-24岁与≥ 45岁之间：12个月疾病的比值比为7.2; 95%置信区间为5.5-9.5）。大麻使用障碍与其他物质使用障碍、情感障碍、焦虑和人格障碍有关。10个月的大麻使用障碍与残疾有关。随着疾病严重程度的增加，几乎所有的关联都变得更强。只有13.2%的终身大麻使用障碍参加了12步程序或专业treatment.Conclusions：DSM-5大麻使用障碍是普遍存在的，与合并症和残疾，并在很大程度上未经治疗。研究结果表明，需要改善预防，并教育公众，专业人员和政策制定者了解与大麻使用障碍和可用干预措施相关的可能危害。
Objective: Attitudes toward marijuana are changing, the prevalence of DSM-IV cannabis use disorder has increased, and DSM-5 modified the cannabis use disorder criteria. Therefore, updated information is needed on the prevalence, demographic characteristics, psychiatric comorbidity, disability, and treatment for DSM-5 cannabis use disorder.Method: In 2012-2013, 36,309 participants >= 18 years old were interviewed in the National Epidemiologic Survey on Alcohol and Related Conditions-III. Psychiatric and substance use disorders were assessed with the Alcohol Use Disorders and Associated Disabilities Interview Schedule-5.Results: The prevalences of 12-month and lifetime cannabis use disorder were 2.5% and 6.3%. Among those with 12-month and lifetime diagnoses, the mean days of marijuana use per year were 225.3 (SE=5.7) and 274.2 (SE=3.8). The odds of 12-month and lifetime cannabis use disorder were higher for men, Native Americans, unmarried individuals, those with low incomes, and young adults (e.g., among those age 18-24 years versus >= 45: odds ratio for 12-month disorder, 7.2; 95% confidence interval, 5.5-9.5). Cannabis use disorder was associated with other substance use disorders, affective disorders, anxiety, and personality disorders. Twelve-month cannabis use disorder was associated with disability. As disorder severity increased, virtually all associations became stronger. Only 13.2% with lifetime cannabis use disorder participated in 12-step programs or professional treatment.Conclusions: DSM-5 cannabis use disorder is prevalent, associated with comorbidity and disability, and largely untreated. Findings suggest the need to improve prevention and educate the public, professionals, and policy makers about possible harms associated with cannabis use disorders and available interventions.